259 related articles for article (PubMed ID: 32086955)
1. Landscape of combination therapy trials in breast cancer brain metastasis.
Fares J; Kanojia D; Rashidi A; Ulasov I; Lesniak MS
Int J Cancer; 2020 Oct; 147(7):1939-1952. PubMed ID: 32086955
[TBL] [Abstract][Full Text] [Related]
2. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
3. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
4. [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Pikó B
Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
8. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
Shah N; Mohammad AS; Saralkar P; Sprowls SA; Vickers SD; John D; Tallman RM; Lucke-Wold BP; Jarrell KE; Pinti M; Nolan RL; Lockman PR
Pharmacol Res; 2018 Jun; 132():47-68. PubMed ID: 29604436
[TBL] [Abstract][Full Text] [Related]
9. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Lin NU; Murthy RK; Abramson V; Anders C; Bachelot T; Bedard PL; Borges V; Cameron D; Carey LA; Chien AJ; Curigliano G; DiGiovanna MP; Gelmon K; Hortobagyi G; Hurvitz SA; Krop I; Loi S; Loibl S; Mueller V; Oliveira M; Paplomata E; Pegram M; Slamon D; Zelnak A; Ramos J; Feng W; Winer E
JAMA Oncol; 2023 Feb; 9(2):197-205. PubMed ID: 36454580
[TBL] [Abstract][Full Text] [Related]
10. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Shawky H; Tawfik H
J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis.
Yu Y; Huang K; Lin Y; Zhang J; Song C
Cancer Med; 2023 Jul; 12(14):15090-15100. PubMed ID: 37255389
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
Petrelli F; Ghidini M; Lonati V; Tomasello G; Borgonovo K; Ghilardi M; Cabiddu M; Barni S
Eur J Cancer; 2017 Oct; 84():141-148. PubMed ID: 28810186
[TBL] [Abstract][Full Text] [Related]
13. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Lin NU; Borges V; Anders C; Murthy RK; Paplomata E; Hamilton E; Hurvitz S; Loi S; Okines A; Abramson V; Bedard PL; Oliveira M; Mueller V; Zelnak A; DiGiovanna MP; Bachelot T; Chien AJ; O'Regan R; Wardley A; Conlin A; Cameron D; Carey L; Curigliano G; Gelmon K; Loibl S; Mayor J; McGoldrick S; An X; Winer EP
J Clin Oncol; 2020 Aug; 38(23):2610-2619. PubMed ID: 32468955
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
15. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Murthy R; Okines A; Paplomata E; Cameron D; Carey LA; Gelmon K; Hortobagyi GN; Krop I; Loibl S; Pegram M; Slamon D; Ramos J; Feng W; Winer E
Ann Oncol; 2022 Mar; 33(3):321-329. PubMed ID: 34954044
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
18. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
[TBL] [Abstract][Full Text] [Related]
19. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
[TBL] [Abstract][Full Text] [Related]
20. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
